Inflammation of the ORAL MUCOSA.
| Excerpt | Reference |
|---|
| "MTX-induced oral mucositis is not related to salivary MTX concentrations, and the use of topical citrovorum therapy or the suppression of salivation does not appear to ameliorate this toxicity." | ( Bleyer, WA; Oliff, A; Poplack, DG, 1979) |
| "Oral mucositis is a complication of head and neck radiotherapy." | ( Rider, CA, 1990) |
| "Oral mucositis is among the complications of head and neck irradiation and systemic chemotherapy." | ( Carl, W; Emrich, LS, 1991) |
| "Oral mucositis is a major toxic effect related to 5-fluorouracil (5-FU) therapy." | ( Dose, AM; Loprinzi, CL, 1990) |
| "Oral mucositis is a frequent side effect of cancer therapy." | ( Burkhead, T; Garewal, HS; Koenig, LM; Vaughn, B; Verdi, CJ, 1995) |
| "Oral mucositis is a common complication of bone marrow transplantation (BMT) conditioning therapy." | ( Barasch, A; Clive, J; D'Ambrosio, JA; Franquin, JC; Nuki, K; Peterson, DE; Schubert, MM; Tanzer, JM; Tutschka, P, 1995) |
| "Oral mucositis is a dose-limiting toxicity of high-dose etoposide regimens." | ( Malik, S; Oblon, DJ; Oblon, MB; Paul, SR, 1997) |
| "Oral mucositis is a frequent complication of radiochemotherapy." | ( Adamietz, IA; Böttcher, HD; Fleischer, W; Rahn, R; Reimer, K; Schäfer, V, 1998) |
| "Oral mucositis is a frequent complication of radiochemotherapy." | ( Adamietz, IA; Böttcher, HD; Fleischer, W; Rahn, R; Reimer, K; Schäfer, V, 1998) |
| "Painful oral mucositis is a common complication after bone marrow transplantation (BMT)." | ( Anderson, PM; Nicklow, R; Ramsay, NK; Rogosheske, J; Rydholm, N; Shu, XO; Skubitz, KM; Weisdorf, DJ, 1998) |
| "Oral mucositis is a dose-limiting toxicity of 5-fluorouracil (5-FU)." | ( Awde, JD; Ghandi, H; Kocha, WI; McCarthy, GM; Vincent, M, 1998) |
| "Oral mucositis is a frequent and potentially severe complication of chemotherapy which has a considerable impact on patient quality of life." | ( Feld, R; Knox, JJ; Puodziunas, AL, 2000) |
| "Oral mucositis is a frequent and potentially severe complication of cancer chemotherapy." | ( Al-Khafaji, AH; Cornell, CJ; Dewhirst, WE; Quill, TJ, 2001) |
| "Oral mucositis is a treatment limiting toxicity of cancer therapy." | ( Allison, C; Epstein, JB; Epstein, MS; Le, ND; Oien, H; Truelove, EL, 2001) |
| "Oral mucositis is the most frequent and severe complication of chemotherapy in children with cancer that can aggravate the child's clinical condition and increase the risk of infection." | ( Chang, AM; Cheng, KK; Cheung, SS; Molassiotis, A; Wai, WC, 2001) |
| "Oral mucositis is a common side-effect of oncology therapies and other diseases." | ( Smith, T, 2001) |
| "Oral mucositis is a common side effect of chemotherapy, with a multifactorial etiology: the direct toxicity of cancer therapy on the normal cells, reduced immunitary defences, presence of bacteria in the oral cavity." | ( Angius, A; Farris, A; Lugliè, PF; Mura, A; Mura, G; Soru, G, 2002) |
| "Oral mucositis is the dose-limiting toxicity for patients receiving concurrent chemoradiotherapy regimens for tumors of the head and neck area." | ( Bonomi, MR; Cerchietti, LC; Menéndez, PR; Navigante, AH; Pogany, CE; Roth, BM; Zaderajko, MA, 2002) |
| "Oral mucositis is one of the major toxicities caused by radiation therapy (RT) treatments to the head and neck." | ( Dodd, MJ; Facione, N; Greenspan, D; MacPhail, L; Miaskowski, C; Paul, SM; Shiba, G; Shih, AS, 2003) |
| "Oral mucositis is a complication common to many cancer therapies and produces considerable pain and morbidity." | ( Clark, RE; Johansen, E; Martuscelli, G; Miller, KB; O'Loughlin, KT; Papas, AS, 2003) |
| "Oral mucositis is a common, treatment-limiting, and costly side effect of cancer treatments whose biological underpinnings remain poorly understood." | ( Baroukh, B; Barritault, D; Caruelle, JP; Godeau, G; Ledoux, D; Morvan, FO; Saffar, JL, 2004) |
| "Oral mucositis is a nearly universal and often severe complication following hematopoietic cell transplantation (HCT)." | ( Bruemmer, B; Lloid, ME; Potter, JD; Robien, K; Schubert, MM; Ulrich, CM, 2004) |
| "Oral mucositis is a frequent and potentially severe complication of radiation or chemotherapy for cancer." | ( Aksungur, P; Iskit, AB; Senel, S; Squier, CA; Sungur, A; Unal, S, 2004) |
| "Oral mucositis is inflammation of the mucosal oral and oropharyngeal tissues." | ( , 2004) |
| "Oral mucositis is a known complication of methotrexate (MTX) therapy, but a single efficacious intervention or agent for prophylaxis or management of this side effect has not yet been identified." | ( Babalis, DE; Ganotakis, ES; Mazokopakis, EE; Papadakis, JA; Vrentzos, GE, 2005) |
| "Oral mucositis is a common and significant toxicity of cancer chemotherapy." | ( Feld, R; Knox, J; Wright, J, 2005) |
| "Oral mucositis is a frequent side-effect of cancer therapy." | ( Augusto, RF; Brito, GA; Cunha, FQ; Falcão, BA; Leitão, BT; Lima, V; Rebouças, CG; Ribeiro, RA; Souza, ML, 2005) |
| "Severe oral mucositis is a major cause of morbidity following allogeneic hematopoietic stem cell transplantation (AHSCT)." | ( Alberani, F; Altieri, MC; Arpinati, M; Baccarani, M; Bandini, G; Banfi, M; Barzetti, L; Berni, M; Bonifazi, F; Borrelli, C; Bosi, A; Brignoli, C; Calza, S; Costazza, G; De Vivo, A; Errico, A; Feraut, C; Gori, E; Leanza, S; Loddo, MC; Mega, A; Pirola, E; Polato, E; Sabbi, V, 2007) |
| "Oral mucositis is a common acute morbidity associated with radiation and/or chemotherapy treatment for cancer." | ( Campbell, KC; Hamilton, CA; Hamstra, DA; Khanna, D; Markwart, SM; Rehemtulla, A; Ross, BD; Sunkara, P; Vuyyuri, SB, 2008) |
| "(1) Oral mucositis is a frequent adverse effect of cancer chemotherapy and radiotherapy." | ( , 2008) |
| "Oral mucositis is a major toxicity associated with high-dose methotrexate (HD-MTX) therapy in the treatment of children with acute lymphoblastic leukaemia and osteosarcoma." | ( Cheng, KK, 2008) |
| "Oral mucositis is a frequent problem after high-dose methotrexate (HD-MTX), impairing patient's quality of life, leading to higher rates of infections and delaying subsequent chemotherapy." | ( Berdel, WE; Bieker, R; Mesters, RM; Müller-Tidow, C; Rudat, A; Schliemann, C; Schmidt, E; Thoennissen, NH; Zühlsdorf, M, 2008) |
| "Oral mucositis is a frequent and significant side effect of chemotherapy and/or radiation therapy." | ( Gomes, MF; Niccoli-Filho, W; Rangel, DC; Teixeira, RT; Vilela-Goulart, Md, 2008) |
| "Oral mucositis is a major toxicity in the high-dose methotrexate (HD-MTX) treatment for children with acute lymphoblastic leukemia (ALL)." | ( Chayama, K; Egawa, T; Gomita, Y; Hayashi, Y; Kaji, H; Kitamura, Y; Maiguma, T; Morishima, T; Sendo, T; Teshima, D; Ueshima, S, 2008) |
| "Oral mucositis is a common side effect induced by radio/chemotherapy in patients with head and neck cancer." | ( Auperin, A; Barritault, D; Biti, G; Bourhis, J; Castaing, M; Deutsch, E; Frascogna, V; Mangoni, M; Morin, C; Opolon, P; Tao, Y; Violot, D; Vozenin-Brotons, MC; Yue, X, 2009) |
| "Oral mucositis is a severe, dose-limiting side effect of radio(chemo)therapy for head and neck tumors." | ( Dörr, W; Haagen, J; Krohn, H; Röllig, S; Schmidt, M; Wolfram, K, 2009) |
| "Oral mucositis is frequent but serious adverse event associated with radiotherapy or radiochemotherapy in head and neck cancer severely impairs health-related quality of life, leading to poor prognosis due to discontinuation of the therapy." | ( Ishihara, M; Itoh, Y; Matsuura, K; Mizuta, K; Watanabe, T, 2010) |
| "Oral mucositis is a common complication in the treatment of cancer." | ( Bussadori, SK; Fernandes, KP; Lopez, TC; Martins, MA; Martins, MD; Mesquita-Ferrari, RA; Pavesi, VC; Sant'Ana Filho, M, 2011) |
| "The incidence of oral mucositis is not closely correlated with DSB repair under the evaluated conditions." | ( Derschang, S; Fleckenstein, J; Fricke, A; Gräber, S; Kühne, M; Melchior, P; Rübe, C; Rübe, CE; Seegmüller, K, 2011) |
| "Oral mucositis is a major complication of concurrent chemoradiotherapy (CRT) in head-and-neck cancer patients." | ( Antequera, R; de Castro, G; Federico, MH; Gil, E; Gouvêa de Lima, A; Rosalmeida, MC; Snitcovsky, IM; Villar, RC, 2012) |
| "Oral mucositis is an inflammatory disease of the mucosa lining oral cavity which leads to atrophy of the epithelium and to its ulceration to form chronic lesions." | ( Bonferoni, MC; Caramella, C; Del Fante, C; Ferrari, F; Gallanti, A; Perotti, C; Rossi, S; Sandri, G, 2011) |
| "Oral mucositis is a frequent and serious complication in patients receiving chemo-radiotherapy for head and neck squamous cell carcinoma." | ( Bahadur, S; Chaudhary, SP; Mohanti, BK; Rath, GK; Sharma, A; Thakar, A, 2012) |
| "Oral mucositis is a frequent complication, but is poorly studied among patients with solid tumors." | ( Fukazawa, M; Kashiwaba, K; Kawaguchi, H; Koga, C; Mori, E; Nakamura, Y; Nishimura, S; Ohno, S; Satou, S; Sawamura, K; Shigematsu, H, 2012) |
| "Oral mucositis is an important dose-limiting and costly side effect of cancer chemotherapy." | ( Bitencourt, FS; Brito, GA; de Alencar, NM; Freitas, AP; Lima-Júnior, RC; Ramos, MV; Ribeiro, RA; Vale, ML, 2012) |
| "Oral mucositis is a frequent adverse effect of cytotoxic chemotherapy, but has not been reported with bevacizumab." | ( Cuellar, S; Popa, AM; Radhakrishnan, L; Valla, K; Villano, JL, 2012) |
| "Oral mucositis is one of the most common side-effects of 5-fluorouracil (5-FU)-based chemotherapy." | ( Hayashi, K; Kamata, M; Kojima, H; Nomura, M; Sawada, S, 2013) |
| "Oral mucositis is a severe and often dose-limiting side-effect of cancer therapy that occurs in patients receiving radiotherapy for head and neck cancers." | ( Colley, HE; Eves, PC; Murdoch, C; Pinnock, A; Thornhill, MH, 2013) |
| "Radiation-induced oral mucositis is an acute morbidity seen in patients undergoing treatment for head and neck cancers." | ( Baliga, MS; Dinkar, C; Fayad, R; Rai, MP; Rao, P; Rao, S; Vaishnav, LK, 2014) |
| "Oral mucositis is one of the major side effects of cancer chemotherapy (30-76%) and radiotherapy (over 50%)." | ( Arora, S; Dhawan, N; Kalia, AN; Kumar, K, 2014) |
| "Oral mucositis is often induced in patients receiving cancer chemotherapy treatment." | ( Lee, MC; Nakajima, A; Takahashi, SS; Wada-Takahashi, S; Yoshida, A; Yoshino, F, 2013) |
| "Oral mucositis is a common and irritating complication of chemotherapy and radiotherapy for malignancies." | ( Andisheh Tadbir, A; Ebrahimi, H; Koohi-Hosseinabadi, O; Namazi, F; Tanideh, N, 2014) |
| "Oral mucositis is a major cause of morbidity in high-dose therapy/autologous stem cell transplantation (HDT/ASCT), where microbial colonization has an important pathological implication." | ( François, S; Hamel, JF; Hunault-Berger, M; Ifrah, N; Mercier, M; Moal, F; Moles-Moreau, MP; Orvain, C; Parot-Schinkel, E; Tanguy-Schmidt, A, 2015) |
| "Oral mucositis is one of the most painful side effects found in esophageal squamous cell carcinoma (ESCC) patients treated with chemoradiotherapy." | ( Xing, SZ; Zhang, Y, 2015) |
| "Oral mucositis is a frequent early side effect of radio(chemo)therapy of head-and-neck malignancies." | ( Bozsaky, E; Dörr, W; Gruber, S; Haagen, J; Habelt, B; Puttrich, M; Schmidt, M; Wolfram, K, 2015) |
| "Oral mucositis is one of the most debilitating side effects in patient undergoing chemotherapy or chemoradiotherapy." | ( Biswas, S; Nandakumar, K; Patel, A; Ramalingayya, GV; Shoja, MH, 2014) |
| "Oral mucositis is a frequent adverse event in patients receiving concurrent chemoradiotherapy for head and neck cancer." | ( Futagami, K; Nakagawa, T; Nomoto, S; Ogata, K; Takase, H; Tokunaga, S; Yonekita, H; Yoshimitsu, K, 2014) |
| "Oral mucositis is a reaction to chemoradiation therapy during cancer treatment." | ( Carvalho, MA; Gomes, MF; Lima, Gde M; Salgado, MA; Santana-Melo, Gde F; Severo, MC; Vilela-Goulart, Md, 2015) |
| "Oral mucositis is a common complication of cancer treatment that may negatively impact the patient's cancer treatment outcome." | ( Sonis, ST; Villa, A, 2015) |
| "Oral mucositis is a common adverse reaction to radiotherapy for head and neck cancer, and there are concerns regarding a decreased quality of life in patients receiving radiotherapy." | ( Horii, K; Kanayama, T; Kawai, T; Miyamoto, H; Shibamoto, Y; Shibuya, Y; Shigetomi, T; Tsuchimochi, T, 2015) |
| "Oral mucositis is a side effect of chemotherapy, head and neck radiotherapy, and targeted therapy, affecting over 75% of high risk patients." | ( Clarkson, JE; Glenny, AM; Littlewood, A; McCabe, MG; Riley, P; Worthington, HV, 2015) |
| "Oral mucositis is a common side effect of allogeneic stem cell transplantation and can lead to increased morbidity, mortality and higher costs." | ( Aerts, E; Kröner, A; Schanz, U; Spirig, R, 2016) |
| "Oral mucositis is a common, dose-limiting early side effect of radio(chemo)therapy for head-and-neck tumors." | ( Dörr, W; Frings, K; Gruber, S; Kleiter, M; Kuess, P, 2016) |
| "Oral mucositis is a common debilitating condition in patients with cancer receiving cytotoxic therapies." | ( Andisheh-Tadbir, A; Davarmanesh, M; Koohi-Hosseinabadi, O; Mehriar, P; Ranjbar, Z; Tanideh, N, 2017) |
| "Oral mucositis is a common adverse effect of Methotrexate (MTX) that may limit its clinical use." | ( Ahmed, AA; El-Sayed, NM; Selim, MA, 2017) |
| "Oral mucositis is especially of concern, due to the morbidity that it causes." | ( Cherubini, K; Cuba, LF; Figueiredo, MAZ; Salum, FG, 2017) |
| "Oral mucositis is a common and serious side effect in patients who undergo cytotoxic cancer therapies." | ( Nakashima, T; Sakurai, K; Uematsu, N, 2017) |
| "Oral mucositis is a common and often debilitating complication among cancer patients receiving radiation therapy to the head and neck or chemotherapy agents, or undergoing hematopoietic stem cell transplantation." | ( Chai, T; Huh, B; Nouri, K; Roldan, CJ, 2017) |
| "Oral mucositis is a common complication in pediatric cancer patients, affecting up to 80% of children." | ( Amadori, F; Bardellini, E; Foresti, I; Majorana, A; Schumacher, RF, 2017) |
| "Rash and oral mucositis are major non-haematological adverse events (AEs) of docetaxel, in addition to fatigue, nausea, vomiting and diarrhoea, which restrict the use of the drug in cancer therapy." | ( Annuar, MABA; Ho, GF; Jabir, RS; Stanslas, J, 2018) |
| "Oral mucositis is a major cause of pain and delayed cancer treatment leading to poor survival in head and neck cancer patients receiving concurrent chemoradiation." | ( Hurst, C; Johns, J; Johns, NP; Khuayjarernpanishk, T; Onseng, K; Priprem, A; Subongkot, S, 2017) |
| "Oral mucositis is inflammation of mucosa of oral cavity which is an inevitable and acute side effect in patients undergoing chemoradiotherapy for head & neck cancer." | ( Chaitanya, B; Chhaparwal, Y; Fernandes, D; Pai, KM; Yathiraj, PH, 2017) |
| "Oral mucositis is a side effect of treatment regimens containing 5-fluorouracil (5-FU)." | ( Biti, G; Bonomo, P; Castiglione, F; Desideri, I; Francolini, G; Gerini, C; Grassi, R; Greto, D; Livi, L; Loi, M; Mangoni, M; Meattini, I; Perna, M; Salvatore, G; Sottili, M, 2018) |
| "Oral mucositis is a common side effect of cancer chemotherapy, with significant adverse impact on the delivery of anti-neoplastic treatment." | ( Bertolini, M; Diaz, PI; Dongari-Bagtzoglou, A; Peterson, DE; Sobue, T; Thompson, A, 2018) |
| "Oral mucositis is one of the most common adverse effects of chemotherapy and radiotherapy." | ( Cabrera-Jaime, S; Estrada-Masllorens, JM; Fernández-Ortega, P; Ferro-García, T; Giner-Boya, P; Icart-Isern, T; Martínez, C, 2018) |
| "Oral mucositis is a frequent, dose-limiting side effect of radio(chemo)therapy of head-and-neck malignancies." | ( Dörr, W; Frings, K; Gruber, S; Kuess, P, 2018) |
| "Oral mucositis is one of the most common side effects induced by cancer therapy, and the prevention or rapid treatment of the symptoms of oral mucositis can improve patients' quality of life and reduce the need for treatment interruption." | ( Kamiki, Y; Makino, K; Takeuchi, I, 2018) |
| "Oral mucositis is the most frequently occurring early side effect of head-and-neck cancer radiotherapy." | ( Arnold, M; Cini, N; Dörr, W; Gernedl, V; Gruber, S; Hetzendorfer, S; Kowald, LM; Kuess, P; Mayer, J; Morava, S; Pfaffinger, S; Rohorzka, A, 2018) |
| "Oral mucositis is one of the most prevalent side effects in patients undergoing radiation therapy for head and neck cancers." | ( Bai, F; Cong, Y; Peng, R; Shan, Y; Tang, H; Wang, L; Yang, C; Yu, Z; Zhou, P, 2018) |
| "Oral mucositis is frequently a toxic effect of chemotherapeutic and/or radiotherapeutic treatment, resulting from complex multifaceted biological events involving DNA damage." | ( Alves, MTS; Caran, EMM; Lopes, NNF; Sá, OMS, 2018) |
| "Oral mucositis is an important adverse effect of chemotherapy, and its severity, frequency, and impact on patient quality of life should not be underestimated." | ( Fushida, S; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohta, T; Okamoto, K; Tajima, H; Takamura, H; Terai, S; Yamaguchi, T, 2019) |
| "Oral mucositis is especially frequent and severe in patients with head and neck squamous cell carcinoma (HNSCC), who receive radiotherapy or chemoradiation." | ( Christiansen, S; Gatzemeier, F; Münscher, A; Rieckmann, T; Rothkamm, K, 2019) |
| "Oral mucositis is one of the most common reasons for discontinuation of S-1 adjuvant chemotherapy after radical gastrectomy." | ( Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Ogata, K; Suzuki, M; Toyomasu, Y; Yanai, M; Yanoma, T, 2019) |
| "Oral mucositis is one of the most frequent complications after chemotherapy or radiotherapy or a combination of both." | ( Männle, H; Münstedt, K, 2019) |
| "Oral mucositis is among the most common tissue toxicities associated with both cytotoxic cancer regimens and head and neck radiotherapy." | ( Giaquinto, A; Nigro, O; Pinotti, G; Tartaro, T; Tuzi, A; Vallini, I, 2020) |
| "Oral mucositis is a significant side effect in cancer treatment." | ( Makino, K; Takeuchi, I; Togo, C, 2019) |
| "Oral mucositis is a common complication of cytotoxic radiotherapy and/or chemotherapy." | ( Hewlings, S; Kalman, D, 2020) |
| "Oral mucositis is a debilitating inflammatory disorder observed in patients undergoing active cancer treatment, particularly cancer of the head and neck region." | ( Baselyous, O; Celentano, A; Cirillo, N; Dao, E; Huang, K; McCullough, M; Mithwani, MA; Paolini, R; Tran, AN; Yap, T; Yiannis, C; Zeng, C, 2020) |
| "Oral mucositis is a common inflammatory complication among patients with cancer." | ( Andisheh-Tadbir, A; Badie, A; Habibagahi, R; Haghnegahdar, S; Koohi-Hosseinabadi, O; Tanideh, N, 2020) |
| "Oral mucositis is a common and distressing complication in patients receiving high-dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT)." | ( Hayashi, H; Itoh, Y; Kasahara, S; Kato-Hayashi, H; Kitagawa, J; Kobayashi, R; Nagata, Y; Ohata, K; Ono, T; Sawada, M; Shimizu, M; Suzuki, A; Tsurumi, H, 2021) |
| "Oral mucositis is a complication of cancer therapy, causing severe pain that affects oral functioning, nutrition, and quality of life, as well as therapy nonadherence or dose-limiting toxicity." | ( Bruera, E; Chung, M; Feng, L; Roldan, CJ, 2021) |
| "Oral mucositis is one of the most common adverse effects of radiation and chemotherapy in treatments of cancers." | ( Ashihara, M; Hashimoto, T; Kashiwagura, Y; Kokubu, C; Namiki, N; Oshiro-Sembokuya, M; Tanaka, S; Uchida, S, 2021) |
| "Acute oral mucositis is a common occurrence in locally advanced-HNSCC patients receiving chemoradiotherapy." | ( Joshi, A; Lashkar, SG; Mathrudev, V; Menon, N; Noronha, V; Patil, VM; Prabhash, K; Satam, KN; Singh, GK, 2021) |
| "Oral mucositis is the most common toxicity of chemoradiotherapy treatment of head and neck cancers." | ( Gothwal, RS; Gupta, AK; Sharma, LM; Sharma, S; Singhal, H; Soni, TP, 2022) |
| "Oral mucositis is a common adverse reaction of radiotherapy used for head and neck cancers." | ( Friedemann, T; Pan, J; Yang, L, 2021) |
| "Oral mucositis is one of the most emerging and debilitating complications of chemotherapy during the treatment period, which strongly affects the nutritional status and physical and mental condition of these patients." | ( Kamallan, SR; Khazaei, S; Mohammadi, F; Oshvandi, K; Ranjbar, H; Vafaei, SY, 2021) |
| "Oral mucositis is a debilitating oncology treatment side effect, with honey identified as a viable management option due to established wound-healing abilities." | ( Hunter, M; McKune, A; Naumovski, N; Toohey, K, 2022) |
| "Oral mucositis is the most debilitating and troublesome adverse effect of irinotecan (CPT-11) treatment." | ( Arafat, EA; El-Khair, SMA; Elsamanoudy, AZ; Shabaan, DA, 2021) |
| "Oral mucositis is a painful condition that occurs in patients who undergo chemotherapy." | ( Bissoli, NS; Bonela, LAS; Gonçalves, WL; Gouvea, SA; Menezes, BC; Oliveira, KG; Sartorio, CL; Thebit, MM, 2021) |
| "Oral mucositis is one of the most disabling adverse events, and clinical guidelines do not take into account nutritional interventions." | ( Cabañas-Alite, L; García-Gozalbo, B, 2021) |
| "Radiation-induced oral mucositis is a major adverse event of radiotherapy." | ( Dong, Q; Dong, X; Feng, Y; Hong, Y; Jiang, Z; Li, H; Liu, H; Liuyang, Z; Tao, J; Wang, G; Wang, Y; Xie, A; Zhang, J, 2021) |
| "Oral mucositis is the most common complication of nasopharyngeal carcinoma during chemoradiotherapy; it decreases the patient's quality of life, and ideal mucosal protective agents are lacking." | ( Hu, K; Jiang, L; Liang, L; Lin, Z; Liu, Z; Ning, X; Shi, Z; Wang, H; Wang, R; Wei, Y; Yan, H; Zhu, H, 2022) |
| "Oral mucositis is a common complication induced by radiation in head and neck cancer patients." | ( Isfahani, MN; Karimi, F; Pakravan, F; Salehabad, NH, 2021) |
| "Oral mucositis is the most common oral complication of cancer patients receiving radiotherapy or chemotherapy, leading to poor quality of life." | ( Chen, J; Chen, L; Jiang, L; Liang, L; Liu, G; Que, L; Wang, R; Zhu, H, 2022) |
| "Radiation-induced oral mucositis is one of the most common adverse events in radiation therapy for head and neck cancers, but treatments for oral mucositis are limited to palliative and supportive care." | ( Katori, Y; Nakayama, Y; Ogawa, T; Ohkoshi, A; Sporn, MB; Taguchi, K; Wakamori, S; Yamamoto, M, 2022) |
| "Radiation-induced oral mucositis is a common and dose-limiting complication of head and neck radiotherapy with no effective treatment." | ( Ala, M; Dehpour, AR; Hejazi, SM; Mahdavi, SR; Mohammad Jafari, R; Tavangar, SM, 2022) |
| "Oral mucositis is a common complication during haematopoietic stem cell transplantation (HSCT)." | ( Clavarino, A; Gavin, NC; Kennedy, GA; Nakagaki, M; Whitfield, K, 2022) |
| "Oral mucositis is a serious issue in patients receiving oncological therapies." | ( Biswasroy, P; Ghosh, G; Haldar, J; Kar, B; Pradhan, D; Rai, VK; Rajwar, TK; Rath, G; Rout, SR; Sarangi, MK, 2023) |
| "The oral mucositis is a mucosal alteration that usually arises from oncological treatments, such as chemotherapy, and it is characterized as an inflammatory process." | ( Alcantara, DDFA; Burbano, RMR; Gomes, JT; Júnior, SMA; Oliveira, CP; Rodrigues, EM; Soares, BM; Soares, RHFC; Tuji, FM; Wanzeler, AMV, 2023) |
| "Oral mucositis is a common side effect of cancer treatment, and in particular of treatment with the mTORC1 inhibitor everolimus." | ( Fei, Q; Lambros, M; Moreno, J; Orlando, R; Parsa, C; Van Haute, L, 2023) |
| "Oral mucositis is a typical adverse effect of chemotherapy, causing oral pain that significantly reduces the patient's quality of life." | ( Kanamura, N; Kishimoto, S; Mazda, O; Nakai, K; Oseko, F; Yamamoto, K; Yamamoto, T; Yamanobe, H, 2023) |
| "Oral mucositis is a common but potentially debilitating complication of stem cell transplant, requiring opioid analgesia in a significant number of cases." | ( Abbas, Y; Ali, M; Hussain, M; Kerio, AA; Khan, MA; Khattak, TA, 2023) |
| "Oral mucositis is a frequently seen complication in the first weeks after hematopoietic stem cell transplantation recipients which can severely affects patients quality of life." | ( Blijlevens, NMA; Brennan, MT; Hazenberg, MD; Huysmans, MCDNJM; Laheij, AMGA; Potting, CMJ; Proctor, GB; Raber-Durlacher, JE; Rozema, FR; Staes, A; van Leeuwen, SJM; von Bültzingslöwen, I, 2023) |
| Excerpt | Reference |
|---|
| "The pattern of oral mucositis and related treatment variables was studied in 20 bone marrow transplant patients." | ( Ortlieb, ML; Parkerson, SG; Spitzer, T; Zerbe, MB, 1992) |
| "The occurrence of severe oral mucositis and delayed bone marrow recovery was schedule dependent, being substantially lower with earlier administration of the anthracycline-intensified regimen on days -12 and -11 before BMT (cohort 3), in comparison with later administration (cohorts 1 and 2)." | ( de Witte, T; Dompeling, E; Donnelly, P; Linssen, P; Minderman, H; Muus, P; Schattenberg, A, 1993) |
| "The mean of oral mucositis peak scores was significantly lower in the tretinoin-treated patients vs the non-treated patients (score 1." | ( Cohen, G; Elad, S; Galili, D; Garfunkel, AA; Or, R, 1997) |
| "We evaluated the grading of oral mucositis daily fraction at each day of treatment until 45 Gy/25 fractions." | ( Chen, HC; Fang, FM; Hsiung, CY; Hsu, HC; Huang, EY; Leung, SW; Sun, LM; Wang, CJ; Yeh, SA, 2000) |
| "World Health Organization (WHO) oral mucositis scores were collected prospectively from the start of chemotherapy (d 1) until d 28 or discharge." | ( Bloor, R; Chang, J; Fraser, CJ; Jayson, GC; Morgenstern, GR; Scarffe, JH; Swindell, R; Wardley, AM, 2000) |
| "Chemotherapy-induced oral mucositis can result in inadequate oral intake, local and systemic infection, a prolonged hospital stay, and increased cost of treatment." | ( Haveman, CW; Redding, SW, 1999) |
| "A modified oral mucositis assessment scale (OMAS) has been found to be a reproducible and effective tool for monitoring mucositis after radiation therapy or chemotherapy." | ( Andresen, S; Bernhard, L; Bolwell, BJ; Kalaycio, M; Kohuth, J; Kuczkowski, E; Lomax, R; Mendiola, S; Pohlman, B; Rybicki, L; Sobecks, R, 2002) |
| "We scored oral mucositis and gut toxicity and measured sugar permeability testing among 56 recipients of a haematopoietic stem cell transplant (HSCT) given myeloablative conditioning with idarubicin, cyclophosphamide and TBI, and a group of 18 patients given cytotoxic chemotherapy for newly diagnosed acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS)." | ( Blijlevens, NM; de Pauw, BE; Donnelly, JP; M'Rabet, L; van't Land, B, 2004) |
| "This program discussed the biology of oral mucositis and its effect on cancer therapy outcomes." | ( , 2004) |
| "We report a case of MTX-induced oral mucositis in a patient with rheumatoid arthritis, who was successfully treated with Wild chamomile mouthwashes." | ( Babalis, DE; Ganotakis, ES; Mazokopakis, EE; Papadakis, JA; Vrentzos, GE, 2005) |
| "the severity of oral mucositis was less than would be expected in these patients without anti-mucositis therapy." | ( Horvath, N; Keefe, D; Lees, J, 2006) |
| "GOAL OF THE WORK: Oral mucositis (OM) is a functionally destructive complication of aggressive head and neck cancer therapy, often resulting in intense pain, an inability to eat and drink and secondary malnutrition and dehydration." | ( Barber, C; Ellis, A; Hewett, J; Powell, R, 2007) |
| "Chemotherapy-induced oral mucositis and diarrhea were scored on a World Health Organization toxicity scale." | ( de Koning, BA; de Laat, PC; Pieters, R; van der Schoor, SR; van Goudoever, JB; Wattimena, DL, 2007) |
| "The Prospective Oral Mucositis Audit assessed the incidence, duration, and determinants of severe oral mucositis (OM; WHO oral toxicity scale grades 3 to 4) in patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) receiving high-dose conditioning chemotherapy before autologous stem-cell transplantation." | ( Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vokurka, S, 2008) |
| "(6) In practice, prevention of oral mucositis due to cancer chemotherapy or radiotherapy is based on orodental care and ice rather than drugs." | ( , 2008) |
| "Chemotherapy-induced oral mucositis is a frequent therapeutic challenge in cancer patients." | ( Figliolia, SL; Lauris, JR; Maurício, AR; Mello de Andrea, ML; Oliveira, DT; Pereira, MC, 2008) |
| "The Prospective Oral Mucositis Audit was an observational study in 197 patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) undergoing, respectively, high-dose melphalan or BEAM chemotherapy and autologous SCT at 25 European centres." | ( Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vorkurka, S, 2009) |
| "Those with oral mucositis (OM) resulting from high-dose chemotherapy or irradiation are the most at risk for painful lesions that lead to significant morbidity and mortality, decreased quality of life and increased economic costs." | ( Buchsel, PC, 2008) |
| "The relationship between oral mucositis and MTX serum concentrations 48 and 72 h after administration was determined." | ( Chayama, K; Egawa, T; Gomita, Y; Hayashi, Y; Kaji, H; Kitamura, Y; Maiguma, T; Morishima, T; Sendo, T; Teshima, D; Ueshima, S, 2008) |
| "For the treatment of oral mucositis, carrageenan microspheres containing allopurinol and local anesthetic agents, such as lidocaine hydrochloride, dibucaine hydrochloride and tetracaine hydrochloride were prepared using a spray-drying method." | ( Asahiyama, M; Inagi, T; Kanebako, M; Makino, K; Nakajima, T; Ohtsuki, E; Terada, H; Tomoda, K, 2009) |
| "Chamomile proved effective in the treatment of oral mucositis in a hamster model." | ( Bussadori, SK; Fernandes, KP; Lopez, TC; Martins, MA; Martins, MD; Mesquita-Ferrari, RA; Pavesi, VC; Sant'Ana Filho, M, 2011) |
| "Stomatitis, including oral mucositis and ulcerations induced by HSV-reactivation are major sources of morbidity after high-dose (HD) chemotherapy and subsequent autologous hematopoietic stem cell transplantation (SCT)." | ( Cornely, OA; Keulertz, C; Lövenich, H; Rüping, MJ; Söhngen, D; Vehreschild, JJ; Wieland, U, 2011) |
| "Severe oral mucositis was seen in 47 (51%) of 92 patients administered palifermin and 63 (67%) of 94 administered placebo (P = ." | ( Alfonsi, M; Bardet, E; Berger, D; Cerezo, L; Chen, MG; Emmerson, L; Foa, P; Giralt, J; Henke, M; Lizambri, R; Salzwimmer, M, 2011) |
| "Deleterious oral mucositis (OM) develops during radiotherapy (RT) or chemoradiotherapy for head-and-neck cancer (HNC) patients." | ( Chung, YL; Jen, YM; Lin, YH; Wang, LW; Yen, SH, 2012) |
| "Folinic acid (FA) as treatment for oral mucositis toxicity was used at investigator discretion in 72 of 140." | ( Bardy, P; Diviney, M; Grigg, A; Holdsworth, R; Hoyt, R; King-Kallimanis, B; McCluskey, J; Murphy, NM; Szer, J; Tait, BD, 2012) |
| "New methods are needed to prevent and treat oral mucositis in patients receiving anthracycline- based chemotherapy(FEC100)." | ( Fukazawa, M; Kashiwaba, K; Kawaguchi, H; Koga, C; Mori, E; Nakamura, Y; Nishimura, S; Ohno, S; Satou, S; Sawamura, K; Shigematsu, H, 2012) |
| "Chemotherapy-induced oral mucositis is a common adverse event in breast cancer patients." | ( Kanazawa, A; Kawaguchi, K; Kawata, Y; Kono, Y; Sugitatsu, M; Tsuyuki, S; Yamaguchi, A, 2012) |
| "Chemoradiotherapy (CRT)-induced oral mucositis (OM) adversely affects a patient's oral functions and quality of life (QOL)." | ( Fernandes, DJ; Gautam, AP; Maiya, AG; Nigudgi, S; Vidyasagar, MS, 2013) |
| "Rats with radiation-induced oral mucositis showed decreased oral intake, weight and survival rate, but oral administration of EC significantly restored all three parameters." | ( Kang, SU; Kim, CH; Kim, JH; Oh, YT; Park, KH; Shin, HA; Shin, YS, 2013) |
| "Radiation-induced oral mucositis is an acute morbidity seen in patients undergoing treatment for head and neck cancers." | ( Baliga, MS; Dinkar, C; Fayad, R; Rai, MP; Rao, P; Rao, S; Vaishnav, LK, 2014) |
| "Current palliative treatments of oral mucositis include specialized agents like pelifermin, platelet derived factors etc." | ( Arora, S; Dhawan, N; Kalia, AN; Kumar, K, 2014) |
| "Chemotherapy-induced oral mucositis (COM) is characterized by painful inflammation with prolonged damage that involves the pathological pain-evoking prostaglandin E2 (PGE2)." | ( Kaneko, A; Kono, T; Matsumoto, C; Miyagi, C; Miyano, K; Mizuhara, Y; Ohbuchi, K; Uezono, Y, 2014) |
| "Painful oral mucositis (OM) is a significant toxicity during radiotherapy for head and neck cancers." | ( Bearden, JD; Dornfeld, KJ; Foote, RL; Klish, MD; Leenstra, JL; Loprinzi, CL; Martenson, JA; Mazurczak, MA; Miller, RC; Novotny, PJ; Puri, DR; Qin, R; Stella, PJ, 2014) |
| "Gastrointestinal toxicity, including oral mucositis, is a frequent complication of intensive combination chemotherapy for acute myeloid leukaemia (AML) and contributes substantially to treatment-related mortality." | ( Bradstock, KF; Collins, M; Cull, G; Di Iulio, J; Enno, A; Hahn, U; Lewis, ID; Link, E; Marlton, P; Schwarer, A; Seymour, JF; Szer, J, 2014) |
| "The incidence of oral mucositis at the start of FEC with or without rebamipide administration was observed in 5 patients in group B (36%) and 38 patients in groups A and C (49%) (p=0." | ( Abe, M; Bamba, N; Enami, A; Makihara, K; Masaoka, M; Masuda, N; Mizutani, M; Shikata, A; Takada, S; Yamamoto, M; Yamamura, J; Yasojima, H, 2014) |
| "Although the management of oral mucositis is essential to improve treatment completion rates, no detailed studies on the time of oral mucositis appearance have been reported." | ( Futagami, K; Nakagawa, T; Nomoto, S; Ogata, K; Takase, H; Tokunaga, S; Yonekita, H; Yoshimitsu, K, 2014) |
| "Chemotherapy-induced oral mucositis is a common adverse event in patients with oral squamous cell carcinoma, and is initiated through a variety of mechanisms, including the generation of reactive oxygen species (ROS)." | ( Aota, K; Azuma, M; Kani, K; Momota, Y; Takano, H; Yamamura, Y; Yamanoi, T, 2015) |
| "In a clinical scenario, oral mucositis affects patients' treatment and quality of life." | ( Aromando, RF; Curotto, P; Farías, RO; Garabalino, MA; Gonzalez, SJ; Heber, EM; Itoiz, ME; Martinel Lamas, DJ; Medina, VA; Monti Hughes, A; Nigg, DW; Pozzi, E; Rivera, ES; Schwint, AE; Thorp, SI; Trivillin, VA, 2015) |
| "Although the incidence of grade ≧2 oral mucositis was lower for patients treated with TJ-14 compared to those treated with placebo, there was no significant difference (48." | ( Aoyama, T; Kataoka, M; Kono, T; Matsuda, C; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Oshiro, M; Sakamoto, J, 2015) |
| "Severe oral mucositis appears inevitable in superselective intra-arterial chemotherapy concurrent with radiotherapy (SSIACRT), requiring management of OM for the patient." | ( Furudate, K; Ito, R; Kimura, H; Kobayashi, W; Kon, T; Kubota, K; Mimura, M; Nakagawa, H; Sakaki, H, 2015) |
| "Chemotherapy-induced oral mucositis (CIOM) is a severe adverse event resulting from cancer chemotherapy." | ( Nakamura, K; Nakamura, M; Onikubo, T; Shinohara, A, 2015) |
| "Both oral mucositis incidence and severity were found to be significantly lower in the cryotherapy group." | ( Chen, J; Fulford, A; Rajakumar, I; Seabrook, J, 2017) |
| "The incidence and severity of oral mucositis, the irradiation period, and the time to discharge in patients who received radiotherapy with head and neck cancer were investigated retrospectively from the medical records." | ( Aoki, M; Fukita, M; Itoh, Y; Kobayashi, R; Kubota, Y; Kuze, B; Mizuta, K; Shakui, T; Sugiyama, T; Suzuki, A, 2016) |
| "Radiation-induced oral mucositis was assessed according to the radiation therapy oncology group criteria." | ( Li, Z; Xudong, H; Yun, G; Zehui, F, 2016) |
| "Forty hamsters with oral mucositis induced by 5-fluorouracil administered on days 0, 5 and 10 and buccal mucosal scratching were randomly divided into four equal groups: group 1 received no additional treatment, group 2 received gel base, and groups 3 and 4 received gels containing 5% and 10% oil, respectively." | ( Andisheh-Tadbir, A; Davarmanesh, M; Koohi-Hosseinabadi, O; Mehriar, P; Ranjbar, Z; Tanideh, N, 2017) |
| "Patients with grade 3 or 4 oral mucositis according to the World Health Organization (WHO) scale as a result of chemotherapy were treated with ketamine mouthwash 20 mg/5 mL four times daily and every 4 h as needed." | ( Craig, M; Cumpston, A; Hamadani, M; Kanate, AS; Shillingburg, A; Wen, S, 2017) |
| "Rash and oral mucositis are major non-haematological adverse events (AEs) of docetaxel, in addition to fatigue, nausea, vomiting and diarrhoea, which restrict the use of the drug in cancer therapy." | ( Annuar, MABA; Ho, GF; Jabir, RS; Stanslas, J, 2018) |
| "Adjuvant melatonin delayed the onset of oral mucositis, which enables uninterrupted cancer treatment and reduced the amount of morphine used for pain treatment." | ( Hurst, C; Johns, J; Johns, NP; Khuayjarernpanishk, T; Onseng, K; Priprem, A; Subongkot, S, 2017) |
| "Chemo-induced oral mucositis (OM) is associated with significant symptoms, treatment delays and increased costs." | ( Armento, G; Biagioli, V; De Marinis, MG; Facchinetti, G; Giannarelli, D; Piredda, M; Tonini, G, 2017) |
| "PDT or LLLT could be used for treatment of oral mucositis in children/young patients." | ( Barbosa Monteiro, MG; Caldas Júnior, AF; da Cruz, MMD; da Motta Silveira, FM; Pina Godoy, G; Ribeiro da Silva, VC, 2018) |
| "Mucositis was measured by the oral mucositis index and World Health Organization mucositis scale on the 4th, 7th, and 14th days after chemotherapy." | ( Pasyar, N; Rambod, M; Ramzi, M, 2018) |
| "Chemotherapy-induced oral mucositis impairs the quality of life." | ( Dote, S; Hira, D; Itakura, S; Kamei, K; Kobayashi, Y; Noda, S; Terada, T, 2018) |
| "In the clinical trial for the treatment of oral mucositis, it was strongly suggested that objective evaluation with a consistent scale would be required." | ( Fujii, M; Konishi, T; Nagamoto, H; Shibasaki, Y; Ueno, T; Yurikusa, T; Zenda, S, 2019) |
| "Development of oral mucositis represents a rate-limiting factor in radiation therapy for the treatment of head and neck, as well as other cancers." | ( Ailing, H; Jian, P; Li, Y, 2019) |
| "Pain due to oral mucositis (OM) is a major problem during concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC) patients." | ( Chen, LM; Chen, QY; Guo, L; He, ZY; Hu, W; Hua, X; Lin, C; Lin, HX; Long, ZQ; Lu, ZJ; Luo, DH; Mai, HQ; Mo, HY; Sun, R; Sun, XQ; Tang, LQ; Wen, W; Zhang, WW; Zhu, Q, 2019) |
| "Oncologists frequently encounter oral mucositis, which can cause unplanned breaks in radiotherapy (RT)." | ( Chen, CH; Chen, F; Chuang, HY; Fang, PT; Huang, CJ; Huang, CM; Huang, MY; Lee, HH; Luo, KH; Wang, YT; Wang, YY; Yuan, SS, 2019) |
| "The incidence of oral mucositis was significantly lower in the treatment group (9." | ( Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Ogata, K; Suzuki, M; Toyomasu, Y; Yanai, M; Yanoma, T, 2019) |
| "Risk and outcome of severe oral mucositis could be ameliorated by oral cryotherapy during the administration of cytotoxic agents for allogeneic HSCT patients receiving non-radiation myeloablative conditioning regimen, and a half-course schedule could acquire a comparable efficacy compared with the whole-course schedule." | ( Jiang, P; Lu, Y; Ma, Q; Teng, S; Wang, H; Wang, J; Wu, D; Zhou, L; Zhu, X, 2020) |
| "Current management of oral mucositis might comprise growth factors and cytokines, anti-inflammatory agents, anesthetics, analgesics, antimicrobial and coating agents, cryotherapy and mucosal protectants." | ( Giaquinto, A; Nigro, O; Pinotti, G; Tartaro, T; Tuzi, A; Vallini, I, 2020) |
| "A chemoradiation-induced oral mucositis model was established by treating mice with concurrent 5-fluorouracil (100 mg/kg, i." | ( Choi, S; Kim, JW; Lee, HR; Shin, SH; Sohn, KY; Yoon, SY, 2020) |
| "The incidence of oral mucositis (any grade) after everolimus treatment is 58% in the general population and 81% in Asian patients." | ( Adachi, M; Amemiya, T; Hata, H; Hayashi, N; Kashiwabara, K; Kikawa, Y; Kondo, N; Mitsunaga, S; Mukai, H; Naito, M; Nakagami, K; Nakatukasa, K; Niikura, N; Ota, Y; Shibuya, Y; Taniike, N; Umeda, M; Watanabe, KI; Yamanaka, T; Yamashita, T, 2020) |
| "A model animal of oral mucositis was prepared by injecting an acetic acid aqueous solution into the buccal mucosa of rats to which a 5-FU solution had been previously administered." | ( Kawamata, R; Makino, K; Takeuchi, I, 2020) |
| "The incidence of severe oral mucositis during chemoradiotherapy was significantly higher and negatively associated with the epidermal growth factor and keratinocyte growth factor levels (p = ." | ( Arita, H; Hiraki, A; Hirayama, M; Hirosue, A; Kawahara, K; Matsuoka, Y; Nagata, M; Nakashima, H; Nakayama, H; Obayashi, Y; Sakata, J; Shinohara, M; Takeshita, H; Yoshida, R, 2021) |
| "Severe oral mucositis caused by chemo- and radio-therapy is a common adverse event in patients with cancer." | ( Kiyomi, A; Kuroda, S; Momo, K; Ono, K; Sugiura, M; Yasu, T, 2020) |
| "Acute oral mucositis has been infrequently studied in the patients with head and neck squamous cell carcinoma (HNSCC) receiving once-weekly cisplatin-based chemoradiotherapy (CRT)." | ( Joshi, A; Lashkar, SG; Mathrudev, V; Menon, N; Noronha, V; Patil, VM; Prabhash, K; Satam, KN; Singh, GK, 2021) |
| "Acute oral mucositis is a common occurrence in locally advanced-HNSCC patients receiving chemoradiotherapy." | ( Joshi, A; Lashkar, SG; Mathrudev, V; Menon, N; Noronha, V; Patil, VM; Prabhash, K; Satam, KN; Singh, GK, 2021) |
| "During cancer treatment, oral mucositis due to radiotherapy or chemotherapy often leads to disruption of the oral mucosa, enabling microbes to invade bloodstream." | ( Hentilä, J; Kankuri, E; Laakamaa, N; Meurman, J; Nikinmaa, S; Pätilä, T; Sorsa, T; Tauriainen, T; Välimaa, H, 2021) |
| "Due to the worsening of oral mucositis, the patient may progress to a worse clinical condition and interrupt antineoplastic treatment." | ( Bissoli, NS; Bonela, LAS; Gonçalves, WL; Gouvea, SA; Menezes, BC; Oliveira, KG; Sartorio, CL; Thebit, MM, 2021) |
| "The weight of the mice, oral mucositis healing score and histopathological examination were used to evaluate the treatment." | ( Fang, W; Fei, F; Gong, A; Li, L; Tang, Y; Yang, M; Yuan, T; Zhang, J, 2021) |
| "Radiation-induced oral mucositis is a major adverse event of radiotherapy." | ( Dong, Q; Dong, X; Feng, Y; Hong, Y; Jiang, Z; Li, H; Liu, H; Liuyang, Z; Tao, J; Wang, G; Wang, Y; Xie, A; Zhang, J, 2021) |
| "Key words: Oral mucositis, Radiotherapy, Licorice, Mucoadhesive film, Placebo." | ( Isfahani, MN; Karimi, F; Pakravan, F; Salehabad, NH, 2021) |
| "Radiation-induced oral mucositis is one of the most common adverse events in radiation therapy for head and neck cancers, but treatments for oral mucositis are limited to palliative and supportive care." | ( Katori, Y; Nakayama, Y; Ogawa, T; Ohkoshi, A; Sporn, MB; Taguchi, K; Wakamori, S; Yamamoto, M, 2022) |
| "Radiation-induced oral mucositis is a common and dose-limiting complication of head and neck radiotherapy with no effective treatment." | ( Ala, M; Dehpour, AR; Hejazi, SM; Mahdavi, SR; Mohammad Jafari, R; Tavangar, SM, 2022) |
| "Chemotherapy-induced oral mucositis (COM) is a common adverse effect of cancer chemotherapy." | ( Hira, D; Imai, S; Ito, M; Itohara, K; Kagawa, M; Matsubara, K; Nakagawa, S; Nakagawa, T; Ogihara, T; Terada, T; Yamanaka, R; Yonezawa, A, 2023) |
| "Unlike intestinal mucositis, most oral mucositis models combined mechanical or chemical irritation with chemotherapy." | ( Cirillo, N; Huang, J; Hwang, AYM; Iskandar, M; Jia, Y; Kim, B; Mohammed, AI, 2022) |
| "Unlike intestinal mucositis, most oral mucositis models combined mechanical or chemical irritation with chemotherapy." | ( Cirillo, N; Huang, J; Hwang, AYM; Iskandar, M; Jia, Y; Kim, B; Mohammed, AI, 2022) |
| "Acute oral mucositis (OM) is a painful complication of concurrent chemoradiotherapy (CCRT)." | ( Chang, HH; Chen, MH; Chen, RS; Chin, HL; Chung, KP; Liu, HC, 2023) |
| "The induction of oral mucositis occurred by the administration of intraperitoneal Fluorouracila (60 mg/kg) and trauma to the mucosa." | ( Alcantara, DDFA; Burbano, RMR; Gomes, JT; Júnior, SMA; Oliveira, CP; Rodrigues, EM; Soares, BM; Soares, RHFC; Tuji, FM; Wanzeler, AMV, 2023) |
| "Radiation-induced oral mucositis (RIOM) is considered to be one of the most important public health problems today, affecting the overall well-being of millions of patients who have received radiotherapy." | ( Feng, M; Gao, Y; Huang, L; Li, S; Li, X; Lin, Y; Yao, Y; Zhang, G; Zhang, T, 2023) |
| "Radiogenic oral mucositis has been a concerning side effect of this treatment method." | ( Cao, J; Chen, X; Liu, R; Wang, X; Zhang, H, 2023) |
| "Considering the prevalence of oral mucositis, we aimed to use the analgesic effects of doxepin with chitosan's antimicrobial and bio-adhesive nature to fabricate a nano-formulation for treating chemotherapy-induced oral mucositis." | ( Amanati, A; Gholami, A; Mardani, M; Rezaee, M; Samiraninezhad, N, 2023) |